Comments
The ongoing healthcare public offers have been fully subscribed on the second day of the three-day bid period. The ₹630-crore Dr Lal PathLabs public issue has been subscribed 2.64 times, according to data provided by the stock exchanges at 5 p.m. on Wednesday.
The QIB portion was subscribed 6.12 times and retail 1.55 times. Meanwhile, the ₹1,344-crore Alkem Laboratories public offer received total subscription of 1.41 times. Qualified institutional buyers bid for 2.33 times of the shares set apart for them, HNIs 0.64 times and retail investors 1.27 times.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.